EN IT

Oncologia Personalizzata

XEPTAGEN SpA è attivamente impegnata nella scoperta e nella validazione di nuovi marcatori per migliorare la gestione clinica del paziente oncologico sviluppando trattamenti terapeutici personalizzati.

Latest Product Literature

Relapse after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C is highly related to development of liver cancer. EASL International Liver Congress (ILC). Amsterdam, Holland. 2017.
Comparison between de-novo occurence and recurrence of hepatocellular carcinoma (HCC) after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C: a real-life cohort study. EASL HCC Summit. Geneva, Switzerland. 2017.
Clinical validation of the iXip index in avoiding unnecessary prostate biopsy: results from a prospective multicenter study involving 426 patients. Cancer Treat Res Comm. 10:40-45. 2017.

Utility of SCCA-IgM levels in the prediction of hepatocellular carcinoma in cirrhotic patients. EASL HCC Summit. Geneva, Switzerland. 2017.
Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in hepatocellular carcinoma patients. Scand J Clin Lab Invest. Epub:1-6. 2017.

Squamous Cellular Carcinoma Antigen serum determination as a biomarker of Barrett esophagus and esophageal cancer: a phase III study. J. Clin. Gastroenterol.. E-pub ahead of print. 2017.


Comunicati stampa

RSS Feed Widget

Youtube

Tweets by Xeptagen